ClinicalTrials.gg
CompletedNCT02638207CIDPUpdated Feb 16, 2021Results posted

Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy

A Phase 3 interventional study of NewGam in Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy, sponsored by Octapharma. Completed at 26 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-02-16.

Sponsored by Octapharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
142
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Study to evaluate the Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy

Read the detailed description

Prospective, Double-blind, Randomized, Multicenter Phase III Study Evaluating Efficacy and Safety of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly(radiculo)neuropathy ("ProCID trial")

02

Conditions studied

  • Chronic Inflammatory Demyelinating Poly(Radiculo)Neuropathy

Keywords

  • Chronic Inflammatory Demyelinating Poly Neuropathy (CIDP)
03

In context

Lead sponsor

Octapharma is the lead sponsor of 71 studies on the registry; 8 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with diagnosis of definite or probable Chronic inflammatory demyelinating polyneuropathy (CIDP) according to the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) Guideline 2010 [van den Bergh et al., 2010]; including patients with Multifocal Acquired Demyelinating Sensory And Motor Neuropathy (MADSAM) or pure motor Chronic inflammatory demyelinating polyneuropathy (CIDP )
  2. Patients currently depending on treatment with immunoglobulins or
  3. Patients with active disease, i.e. not being in remission, who are progressive or relapsing prior to trial start or during the Phase
  4. Weakness of at least 2 limbs
  5. >18 to \<80 years of age
  6. Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 (with a score of 2 coming exclusively from leg disability)
  7. Voluntarily given, fully informed written consent obtained from patient before any study-related procedures are conducted

Exclusion criteria

Exclusion Criteria:

  1. Unifocal forms of Chronic inflammatory demyelinating polyneuropathy (CIDP)
  2. Pure sensory Chronic inflammatory demyelinating polyneuropathy (CIDP)
  3. Multifocal motor neuropathy (MMN) with conduction block [van den Bergh et al., 2010]
  4. Patients who previously failed immunoglobulin treatment
  5. Treatment with immunomodulatory/suppressive agents (cyclosporin, methotrexate, mitoxantrone, mycophenolate mofetil or azathioprine) during the six months prior to baseline visit
  6. Patients on or treated with rituximab, alemtuzumab, cyclophosphamide, or other intensive chemotherapeutic regimens, previous lymphoid irradiation or stem cell transplantation during the 12 months prior to baseline visit
  7. Respiratory impairment requiring mechanical ventilation
  8. Myelopathy or evidence of central nervous system demyelination or significant persisting neurological deficits from stroke, or central nervous system (CNS) trauma
  9. Clinical evidence of peripheral neuropathy from another cause such as

    1. connective tissue disease or systemic lupus erythematosus (SLE)
    2. infection, hepatitis, Lyme disease
    3. cancer (with the exception of basal cell skin cancer)
    4. IgM paraproteinemia with anti-myelin associated glycoprotein antibodies
  10. Diabetic neuropathy
  11. Cardiac insufficiency ( [NYHA] III/IV), cardiomyopathy, significant cardiac dysrhythmia requiring treatment, unstable or advanced ischemic heart disease
  12. Severe liver disease (ALAT 3x > normal value)
  13. Severe kidney disease (creatinine 1.5x > normal value)
  14. , or HIV infection
  15. Thromboembolic events: patients with a history of deep vein thrombosis (DVT) within the last year prior to baseline visit or pulmonary embolism ever; patients with susceptibility to embolism or deep vein thrombosis (DVT)
  16. (BMI) ≥40 kg/m2
  17. Patients with uncompensated hypothyroidism (abnormally high Thyroid-Stimulating Hormone [TSH] and abnormally low Thyroxine [T4]) or known vitamin B12 deficiency if patients don't receive adequate substitution therapy
  18. Medical conditions whose symptoms and effects could alter protein catabolism and/or Immunoglobulin G (IgG) utilization (e.g. protein-losing enteropathies, nephrotic syndrome)
  19. Known Immunoglobulin A (IgA) deficiency with antibodies to Immunoglobulin A (IgA)
  20. History of severe , e.g. anaphylaxis or severe systemic response to immuno-globulin, blood or plasma derived products, or any component of NewGam
  21. Known blood hyperviscosity, or other hypercoagulable states
  22. Use of other blood or plasma-derived products within three months prior to Visit 2
  23. Patients with a past or present history of drug abuse or alcohol abuse within the preceding five years prior to baseline visit
  24. Patients unable or unwilling to understand or comply with the study protocol
  25. Participation in another interventional clinical study with medicinal product (IMP) treatment currently or during the three months prior to Visit 2
  26. Women who are breast feeding, pregnant, or planning to become pregnant, or are unwilling to use an effective method (such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partner) while on study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
142 participants (actual)

Study arms

  • Experimental
    0.5 g/kg NewGam

    All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).

    Drug: NewGam

  • Experimental
    1.0 g/kg NewGam

    All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (1.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).

    Drug: NewGam

  • Experimental
    2.0 g/kg NewGam

    All patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (2.0g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days).

    Drug: NewGam

Interventions

  • DrugNewGam

    In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding

    Also known as: Panzyga

06

What researchers measure

Primary outcomes

  1. Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score

    Efficacy - Proportion of responders in the 1.0 g/kg NewGam arm at Week 24 (Termination Visit) relative to baseline (Week 0). A responder being defined as a patient with a decrease of at least 1 point on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score (a scale from 0 to 10, from healthy to unable to make any purposeful movements with arms and/or legs)

    Time frame: at Week 24

Secondary outcomes

  1. Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score

    Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline compared to the 1.0 g/kg arm, based on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score

    Time frame: at Week 24

  2. Grip Strength Score

    Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline at Week 0 compared to the 1.0 g/kg arm, based on the grip strength (Martin Vigorimeter) using the previously published minimum clinically important difference (MCID) cut-off of 8 kilopascal (kPa)

    Time frame: at Week 24

  3. Inflammatory Rasch-built Overall Disability Scale (I-RODS Score)

    Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline at Week 0 compared to the 1.0 g/kg arm, based on the Inflammatory Rasch-built overall disability scale (I-RODS Score) using the MCID concept related to the varying standard errors (MCID-SE) as recently demonstrated

    Time frame: at Week 24

  4. Worsening in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score

    Time to first confirmed worsening on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale by at least 1 point from the value at baseline (Week 0)

    Time frame: Week 24

  5. Mean Change in Grip Strength

    Mean change from baseline (Week 0) to Termination Visit in grip strength of both hands (assessed by Martin vigorimeter). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point.

    Time frame: Up to 24 weeks

  6. Inflammatory Rasch-built Overall Disability Scale (I-RODS)

    Mean change from baseline (Week 0) to Termination Visit in Inflammatory Rasch-built overall disability sum score (I-RODS using the concept of MCID-SE as recently reported) and number of improvers. The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point. A scale from 0 to 48, from "Not possible to perform" to "Possible without any difficulty". Higher values represent a better outcome.

    Time frame: Up to 24 weeks

  7. Motor Nerves

    Mean change from baseline (Week 0) to Termination Visit in sum of the distal evoked amplitude of 4 right sided and 4 left sided motor nerves (peroneal, tibial, ulnar and median). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point.

    Time frame: Up to 24 weeks

  8. Mean Change in Pain Intensity Numerical Rating Scale (PI-NRS Scale)

    Mean change from baseline (Week 0) to Termination Visit in Pain Intensity Numeric Rating Scale (PI-NRS). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point. The Pain Intensity Numeric Rating Scale (PI-NRS, a numeric scale where 0 = no pain and 10 = worst possible pain) is an 11-point scale for patient self-reporting of pain. A higher value represents a worse outcome.

    Time frame: Up to 24 weeks

  9. Worsening on the Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale)

    Time to first confirmed worsening on the I-RODS scale. The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point. A scale from 0 to 48, from "Not possible to perform" to "Possible without any difficulty". Higher values represent a better outcome. Worsening is determined using the concept of MCID (minimum clinically important difference) using the individually obtained standard errors (MCID-SE).

    Time frame: 24 weeks

  10. 1 Point Decrease in the INCAT Disability Score

    Time to 1 point decrease (improvement of disability) in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score

    Time frame: 24 weeks

  11. Decrease in Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale)

    Time to decrease in Inflammatory Rasch-built overall disability scale (I-RODS) scores

    Time frame: 24 weeks

07

Results

Posted Feb 16, 2021

Participant flow

Participant flow — Overall Study
Milestone0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGam
Started356938
Completed286134
Not completed784

Outcome measures

PrimaryDecrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score

Efficacy - Proportion of responders in the 1.0 g/kg NewGam arm at Week 24 (Termination Visit) relative to baseline (Week 0). A responder being defined as a patient with a decrease of at least 1 point on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score (a scale from 0 to 10, from healthy to unable to make any purposeful movements with arms and/or legs)

Time frame:
at Week 24
Reported as:
Number · proportion of subjects
Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score
proportion of subjects1.0 g/kg NewGam
Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score.7971
SecondaryDecrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score

Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline compared to the 1.0 g/kg arm, based on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score

Time frame:
at Week 24
Reported as:
Number · Proportion of responders
Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score
Proportion of responders0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGam
Decrease in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score.6471.7971.9167
SecondaryGrip Strength Score

Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline at Week 0 compared to the 1.0 g/kg arm, based on the grip strength (Martin Vigorimeter) using the previously published minimum clinically important difference (MCID) cut-off of 8 kilopascal (kPa)

Time frame:
at Week 24
Reported as:
Number · Proportion of responders
Grip Strength Score
Proportion of responders0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGam
Grip Strength Score.5588.6522.8333
SecondaryInflammatory Rasch-built Overall Disability Scale (I-RODS Score)

Proportion of responders in the 0.5 g/kg and 2.0 g/kg NewGam arms at Week 24 relative to baseline at Week 0 compared to the 1.0 g/kg arm, based on the Inflammatory Rasch-built overall disability scale (I-RODS Score) using the MCID concept related to the varying standard errors (MCID-SE) as recently demonstrated

Time frame:
at Week 24
Reported as:
Number · Proportion of responders
Inflammatory Rasch-built Overall Disability Scale (I-RODS Score)
Proportion of responders0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGam
Inflammatory Rasch-built Overall Disability Scale (I-RODS Score).3824.5507.7222
SecondaryWorsening in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score

Time to first confirmed worsening on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability scale by at least 1 point from the value at baseline (Week 0)

Time frame:
Week 24
Reported as:
Median · days
Worsening in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Score
days0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGam
Worsening in the Inflammatory Neuropathy Cause and Treatment (INCAT) Disability ScoreNA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryMean Change in Grip Strength

Mean change from baseline (Week 0) to Termination Visit in grip strength of both hands (assessed by Martin vigorimeter). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point.

Time frame:
Up to 24 weeks
Reported as:
Mean · kPa
Mean Change in Grip Strength
kPa0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGam
Dominant Hand23.91 ± 25.29019.38 ± 20.37726.06 ± 25.030
Non-dominant Hand23.94 ± 24.60017.43 ± 19.91624.53 ± 22.247
SecondaryInflammatory Rasch-built Overall Disability Scale (I-RODS)

Mean change from baseline (Week 0) to Termination Visit in Inflammatory Rasch-built overall disability sum score (I-RODS using the concept of MCID-SE as recently reported) and number of improvers. The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point. A scale from 0 to 48, from "Not possible to perform" to "Possible without any difficulty". Higher values represent a better outcome.

Time frame:
Up to 24 weeks
Reported as:
Mean · score on a scale
Inflammatory Rasch-built Overall Disability Scale (I-RODS)
score on a scale0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGam
Inflammatory Rasch-built Overall Disability Scale (I-RODS)11.38 ± 12.48510.32 ± 10.83613.86 ± 11.981
SecondaryMotor Nerves

Mean change from baseline (Week 0) to Termination Visit in sum of the distal evoked amplitude of 4 right sided and 4 left sided motor nerves (peroneal, tibial, ulnar and median). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point.

Time frame:
Up to 24 weeks
Reported as:
Mean · mV
Motor Nerves
mV0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGam
Motor Nerves2.16 ± 6.3322.69 ± 6.6883.93 ± 9.298
SecondaryMean Change in Pain Intensity Numerical Rating Scale (PI-NRS Scale)

Mean change from baseline (Week 0) to Termination Visit in Pain Intensity Numeric Rating Scale (PI-NRS). The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point. The Pain Intensity Numeric Rating Scale (PI-NRS, a numeric scale where 0 = no pain and 10 = worst possible pain) is an 11-point scale for patient self-reporting of pain. A higher value represents a worse outcome.

Time frame:
Up to 24 weeks
Reported as:
Mean · score on a scale
Mean Change in Pain Intensity Numerical Rating Scale (PI-NRS Scale)
score on a scale0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGam
Mean Change in Pain Intensity Numerical Rating Scale (PI-NRS Scale)-2.29 ± 3.040-2.19 ± 2.907-2.17 ± 3.256
SecondaryWorsening on the Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale)

Time to first confirmed worsening on the I-RODS scale. The reported change was calculated from two time points as the value at the later time point minus the value at the earlier time point. A scale from 0 to 48, from "Not possible to perform" to "Possible without any difficulty". Higher values represent a better outcome. Worsening is determined using the concept of MCID (minimum clinically important difference) using the individually obtained standard errors (MCID-SE).

Time frame:
24 weeks
Reported as:
Median · days
Worsening on the Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale)
days0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGam
Worsening on the Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale)NA (NA to NA)NA (NA to NA)NA (NA to NA)
Secondary1 Point Decrease in the INCAT Disability Score

Time to 1 point decrease (improvement of disability) in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score

Time frame:
24 weeks
Reported as:
Median · days
1 Point Decrease in the INCAT Disability Score
days0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGam
1 Point Decrease in the INCAT Disability Score22.0 (22.0 to 24.0)26.0 (22.0 to 43.0)23.0 (22.0 to 43.0)
SecondaryDecrease in Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale)

Time to decrease in Inflammatory Rasch-built overall disability scale (I-RODS) scores

Time frame:
24 weeks
Reported as:
Median · days
Decrease in Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale)
days0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGam
Decrease in Inflammatory Rasch-built Overall Disability Scale (I-RODS Scale)NA (NA to NA)NA (NA to NA)NA (NA to NA)

Adverse events

Collected over Up to 36 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NGAM 0.5 g/kg0/35 (0%)1/35 (2.9%)20/35 (57.1%)
NGAM 1.0 g/kg1/69 (1.4%)4/69 (5.8%)45/69 (65.2%)
NGAM 2.0 g/kg1/38 (2.6%)1/38 (2.6%)24/38 (63.2%)
Total2/142 (1.4%)6/142 (4.2%)88/142 (62%)
Most frequent serious events
Most frequent serious events
EventNGAM 0.5 g/kgNGAM 1.0 g/kgNGAM 2.0 g/kgTotal
OsteonecrosisMusculoskeletal and connective tissue disorders1/350/690/381/142
EncephalitisInfections and infestations0/350/691/381/142
OsteomyelitisInfections and infestations0/351/690/381/142
PneumoniaInfections and infestations0/351/690/381/142
Cardio-respiratory ArrestCardiac disorders0/351/690/381/142
AspirationRespiratory, thoracic and mediastinal disorders0/351/690/381/142
Deafness unilateralEar and labyrinth disorders0/351/690/381/142
HeadacheNervous system disorders0/351/690/381/142
VomitingGastrointestinal disorders0/351/690/381/142
MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/351/690/381/142
Most frequent other events
Showing 10 of 93
Most frequent other events
EventNGAM 0.5 g/kgNGAM 1.0 g/kgNGAM 2.0 g/kgTotal
HeadacheNervous system disorders1/359/698/3819/142
Dermatitis allergicSkin and subcutaneous tissue disorders4/355/694/3813/142
PyrexiaGeneral disorders3/356/692/3811/142
Blood pressure increasedInvestigations3/356/690/389/142
ChillsGeneral disorders3/353/691/387/142
UrticariaSkin and subcutaneous tissue disorders3/350/690/383/142
Body temperature increasedInvestigations2/354/693/389/142
NauseaGastrointestinal disorders1/351/693/385/142
Blood lactate dehydrogenase increasedInvestigations0/355/690/385/142
LeukopeniaBlood and lymphatic system disorders1/355/690/386/142

Baseline characteristics

Age, Continuous
Age, Continuous(years)0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGamTotal
Mean52.49 ± 14.44956.32 ± 14.61658.05 ± 13.76455.84 ± 14.398
Sex: Female, Male
Sex: Female, Male(Participants)0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGamTotal
Female13311458
Male22382484
Race (NIH/OMB)
Race (NIH/OMB)(Participants)0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGamTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White356938142
More than one race0000
Unknown or Not Reported0000
Weight
Weight(kg)0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGamTotal
Mean84.09 ± 16.51181.74 ± 16.33377.68 ± 75.5081.23 ± 79.00
Height
Height(cm)0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGamTotal
Mean173.46 ± 9.506172.81 ± 8.304171.61 ± 9.030172.65 ± 8.770
BMI
BMI(kg/m^2)0.5 g/kg NewGam1.0 g/kg NewGam2.0 g/kg NewGamTotal
Mean27.92 ± 4.87327.27 ± 4.58826.33 ± 5.23127.18 ± 4.837
08

Study locations

26 sites
  • MHAT Puls EOOD
    Blagoevgrad, 2700, Bulgaria
  • St. Naum Hospital
    Sofia, 1797, Bulgaria
  • Toronto General Hospital
    Toronto, Ontario M5G 2C4, Canada
  • Octapharma Research Site
    Montréal, H3A2B4, Canada
  • Outpatient Clinic of Neurology
    Hradec Králové, 500 03, Czechia
  • Regional Hospital Pardubice
    Pardubice, 532 03, Czechia
  • Thomayer Faculty Hospital
    Prague, 140 00, Czechia
  • University Medical Center Goettigen
    Goettigen, 37075, Germany
  • Jahn Ferenc Del Pesti Korhaz
    Budapest, 1204, Hungary
  • Szegedi Tudományegyetem ÁOK Neurológiai Klinika
    Szeged, 6725, Hungary
  • Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie Klinika Neurologii
    Lublin, 20-954, Poland
  • Wojewodzki Szpital Specjalistyczny W Olsztynie
    Olsztyn, 10-561, Poland
  • Uniwersytecki Szpital Kliniczny
    Wrocław, 50-556, Poland
  • Theo Health S.R.L.
    Braşov, 500091, Romania
  • Institutul Clinic Fundeni
    Bucharest, 022328, Romania
  • Spitalul Clinic Judetean de Urgenta "Sf.Apostol Andrei" Constanta
    Constanţa, 900591, Romania
  • Republican Clinical Neurological Centre
    Kazan', 420021, Russian Federation
  • Neurology Research Centre
    Moscow, 125367, Russian Federation
  • Nizhny Novgorod Regional Clinical Hospital N.A. N.A.Semashko
    Nizhny Novgorod, 603126, Russian Federation
  • National Medical Research Centre of Psychiatry and Neurology n.a. V.M.Bekhterev
    Saint Petersburg, 192019, Russian Federation
  • City Multifield Hospital #2
    Saint Petersburg, 194354, Russian Federation
  • Ivano Frankivsk National Medical University
    Ivano-Frankivs'k, 76008, Ukraine
  • National Medical Academy Of Postgraduate Education Named After P.L. Shupyk
    Kyiv, 4112, Ukraine
  • Volyn Regional Clinical Hospital
    Luts'k, 4300, Ukraine
  • Vinnytsia National Medical University
    Vinnytsia, 21005, Ukraine
  • Municipal Institution Zaporizhzhya Regional Clinical Hospital
    Zaporizhzhya, 69600, Ukraine
09

References and documents

Publications

  • Cornblath DR, van Doorn PA, Hartung HP, Merkies ISJ, Katzberg HD, Hinterberger D, Clodi E; ProCID Investigators. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy. Brain. 2022 Apr 29;145(3):887-896. doi: 10.1093/brain/awab422. PubMed 35038723 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2017 to primary completion in Sep 2019, 23 months.

Results were first posted in Feb 2021, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 16, 2015
First posted
Dec 23, 2015
StartActual
Sep 27, 2017
Primary completionActual
Sep 5, 2019
CompletionActual
Sep 5, 2019
Results first posted
Feb 16, 2021
Last update
Feb 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02638207
Lead sponsor
Octapharma
Responsible party
Sponsor
First posted
Dec 23, 2015
Start date
Sep 27, 2017
Primary completion
Sep 5, 2019
Completion
Sep 5, 2019
Results posted
Feb 16, 2021
Last update
Feb 16, 2021

Study contacts

Wolfgang Frenzel, MD
study director · Octapharma

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion